For the quarter ending 2025-03-31, NKGN had -$206K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-03-31 |
|---|---|
| Net income (loss) | 15,350 |
| Depreciation and amortization | 341 |
| Stock-based compensation | 707 |
| Amortization of right-of-use asset | 38 |
| Noncash interest expense (including related party amounts of 237 and 698 for the three months ended march 31, 2025 and 2024, respectively) | 403 |
| Gain on amendments to financial instruments, net | 0 |
| Loss on issuance of financial instruments (including related party amounts of zero and 74 for the three months ended march 31, 2025 and 2024, respectively) | -1,050 |
| Change in fair value of financial instruments (including related party amounts of 1,041 and zero for the three months ended march 31, 2025 and 2024, respectively) | 21,575 |
| Loss on sale of property and equipment, net | 0 |
| Prepaid expenses and other current assets | 128 |
| Accounts payable and accrued expenses | 1,079 |
| Other current liabilities | -25 |
| Operating lease liability | -40 |
| Other, net | 0 |
| Net cash used in operating activities | -2,800 |
| Sales of property and equipment | 0 |
| Purchases of capitalized software | 52 |
| Net cash (used in) provided by investing activities | -52 |
| Proceeds from amendment to and settlements of fpa agreements | 0 |
| Proceeds-Convertible12Promissory Notes | 1,800 |
| Proceeds-Convertible Bridge Loans | 90 |
| Proceeds from issuance of bridge notes | 0 |
| Proceeds from amendment to the pipe warrants | 0 |
| Proceeds from conversion of warrants to common stock | 11 |
| Proceeds from capital contributions | 1,745 |
| Payment of revolving line of credit | 1,000 |
| Payment of transaction costs | 0 |
| Proceeds from repayments of receivables from shareholder | 0 |
| Net cash provided by financing activities | 2,646 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -206 |
| Cash and cash equivalents at beginning of period | 235 |
| Cash and cash equivalents at end of period | 29 |
NKGen Biotech, Inc. (NKGN)
NKGen Biotech, Inc. (NKGN)